Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Sep 21, 2009; 15(35): 4415-4422
Published online Sep 21, 2009. doi: 10.3748/wjg.15.4415
Published online Sep 21, 2009. doi: 10.3748/wjg.15.4415
Table 1 Definition of complications
Complication | ICD-9-CM | Procedure codes | Treatment |
Anemia | 281.xx, 283.xx, 284.xx, 285.xx | ||
Alopecia | 704.0x, A9282 | ||
Asthenia | 780.7x | HCPCS codes G9029-G9032 | |
Constipation | 546.0x | Therapeutic class 150-156 | |
Cough | 786.2x, 786.3x, 786.4x | Therapeutic class 128, 131 | |
Dehydration | 276.50, 276.51 | ||
Dermatitis | 693.0x, 693.8x, 693.9x | ||
Diarrhea | 007.xx, 009.x, 787.91 | Therapeutic class 148 | |
Esophagitis | 530.1x | ||
Fever | 780.6x | ||
Gastritis | 535.xx | ||
Headache | 784.0x | ||
Infection | 001.xx-018.xx, 030.xx-041.xx, 045.xx-057.xx, | Therapeutic class 2-20 | |
070.xx-079.xx, | |||
110.xx-118.xx, 130.xx-136.xx, 480.xx-486.xx, 995.91, 995.92 | |||
Insomnia | 780.51, 780.52 | Therapeutic class 74, Eszopiclone, Zaleplon, Zolpidem Tartrate | |
Mucositis | 528.0x, 528.1x , 528.2x, 528.3x, 528.6, 529.0x, 054.2x | ||
Nausea and vomiting | 787.0x, | CPT codes G9022, G9023, G9024, or | Therapeutic class 160 |
HCPCS codes for antiemetics | |||
Neutropenia | 288.0x | HCPCS codes for neutropenia treatment | |
Night sweats | 780.8x | ||
Weight loss | 783.2x, 783.0x | ||
Complications of vascular access devices | 999.3x, 996.62, 996.74, 512.0x, 512.1x, 512.8x, 287.4x |
Table 2 Baseline demographic and clinical characteristics1 of eligible patients with GEC by index treatment regimen (mean ± SD) n (%)
5-FU (n = 257) | CAP (n = 105) | 5-FU combination (n = 344) | CAP combination (n = 76) | Any 5-FU (n = 540) | Any CAP (n = 166) | Total (n = 1013)1 | |
Demographics2 | |||||||
Female | 180 (70.0) | 77 (73.3) | 264 (76.7) | 61 (80.3) | 395 (73.2) | 127 (76.5) | 746 (73.6) |
Mean age (yr) | 63.2 (12.1) | 63.6 (12.4) | 60.3 (11.6) | 60.4 (12.0) | 61.7 (11.9) | 63.0 (12.3) | 62.6 (11.8) |
Covered by Medicare | 127 (49.4) | 50 (47.6) | 126 (36.6) | 30 (39.5) | 231 (42.8) | 78 (47.0) | 465 (45.9) |
Residing in urban area | 202 (78.6) | 83 (79.1) | 259 (75.3) | 64 (84.2) | 416 (77.0) | 136 (81.9) | 784 (77.4) |
Clinical characteristics3 | |||||||
CCI | 5.5 (3.2) | 5.9 (3.0) | 4.9 (3.0) | 5.1 (3.1) | 5.1 (3.1) | 5.5 (3.0) | 5.2 (3.1) |
CDS | 4.2 (3.5) | 4.5 (3.7) | 4.6 (3.4) | 4.3 (3.5) | 4.4 (3.4) | 4.6 (3.6) | 4.6 (3.5) |
Metastatic disease4 | 161 (62.7) | 55 (52.4) | 248 (72.1) | 47 (61.8) | 364 (67.4) | 97 (58.4) | 675 (66.6) |
Previous treatment | |||||||
Surgery | 125 (48.6) | 27 (25.7) | 46 (13.4) | 11 (14.5) | 154 (28.5) | 34 (20.5) | 239 (23.6) |
Radiotherapy | 115 (44.8) | 25 (23.8) | 162 (47.1) | 15 (19.7) | 252 (46.7) | 40 (24.1) | 410 (40.5) |
Baseline expenditure ($)5 | 5479 (4730) | 4965 (6277) | 4598 (5019) | 4178 (4005) | 5014 (5061) | 4607 (5573) | 4763 (5193) |
Table 3 Distribution of patients by chemotherapy regimen and treatment setting 1n (%)
Chemotherapy regimen | Neoadjuvant (n = 84) | Adjuvant (n = 213) | First-line (n = 743) | Second-line (n = 354) | Any setting (n = 1013) |
All 5-FU-based regimens | 51 (60.7) | 140 (65.7) | 319 (42.9) | 139 (39.3) | 540 (53.5) |
5-FU monotherapy | 16 (19.0) | 104 (48.8) | 89 (12.0) | 68 (19.2) | 257 (25.4) |
5-FU + platinum | 24 (28.6) | 19 (8.9) | 104 (14.0) | 25 (7.1) | 163 (16.1) |
5-FU + platinum + non-platinum | 14 (16.7) | 18 (8.5) | 96 (12.9) | 31 (8.8) | 145 (14.3) |
5-FU + non-platinum | 2 (2.4) | 5 (2.3) | 30 (4.0) | 40 (11.3) | 73 (7.2) |
Capecitabine-based regimens | 4 (4.8) | 24 (11.3) | 90 (12.1) | 72 (20.3) | 166 (16.4) |
Capecitabine monotherapy | 2 (2.4) | 18 (8.5) | 50 (6.7) | 42 (11.9) | 105 (10.4) |
Capecitabine + platinum | 2 (2.4) | 1 (0.5) | 11 (1.5) | 8 (2.3) | 19 (1.9) |
Capecitabine + platinum + non-platinum | 0 (0.0) | 6 (2.8) | 16 (2.2) | 11 (3.1) | 31 (3.1) |
Capecitabine + non-platinum | 0 (0.0) | 1 (0.5) | 13 (1.7) | 19 (5.4) | 32 (3.2) |
Table 4 Frequency of complications (rate per 1000 person-months) in patients with GEC, by treatment regimen
Complication | 5-FU monotherapy | Capecitabine monotherapy | 5-FU combination therapy | Capecitabine combination therapy | Any 5-FU regimen | Any capecitabine regimen |
Bone marrow | 233 | 110 | 349 | 205 | 307 | 151 |
Constitutional symptom | 254 | 108 | 323 | 295 | 293 | 183 |
Gastrointestinal tract symptoms | 465 | 183 | 577 | 284 | 529 | 224 |
Infection | 199 | 114 | 268 | 150 | 238 | 131 |
Skin complications | 0 | 0 | 2 | 0 | 1 | 0 |
Other | 14 | 14 | 22 | 32 | 19 | 22 |
Any complication | 764 | 336 | 835 | 460 | 806 | 387 |
- Citation: Saif MW, Shi N, Zelt S. Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World J Gastroenterol 2009; 15(35): 4415-4422
- URL: https://www.wjgnet.com/1007-9327/full/v15/i35/4415.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.4415